### AGENDA
The Ritz-Carlton Hotel | Washington DC, 1150 22nd Street, NW

**Monday, February 13th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am-5:00 pm</td>
<td>Grant Review Committee Meeting (by invitation)</td>
<td>Plaza Ballroom</td>
</tr>
<tr>
<td>10:30-12:30 pm</td>
<td>MAC internal meeting (by invitation)</td>
<td>Roosevelt</td>
</tr>
<tr>
<td>12:00-6:00 pm</td>
<td>Registration open</td>
<td>Salon Ballroom Foyer</td>
</tr>
<tr>
<td>1:00-5:30 pm</td>
<td>Melanoma Advocates &amp; Foundations Forum (by invitation)</td>
<td>Salon I</td>
</tr>
<tr>
<td>6:00-7:30 pm</td>
<td>Opening Reception</td>
<td>Salon I &amp; II Foyer</td>
</tr>
</tbody>
</table>

**Tuesday, February 14th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am-6:00 pm</td>
<td>Registration open</td>
<td>Outside Salon Ballrooms</td>
</tr>
<tr>
<td>7:00-8:15 am</td>
<td>General Breakfast</td>
<td>Salon III</td>
</tr>
<tr>
<td>7:00-8:15 am</td>
<td>Young Investigators Breakfast (by invitation only)</td>
<td>Plaza Ballroom</td>
</tr>
<tr>
<td>8:30-8:45 am</td>
<td>Opening Remarks</td>
<td>Salon I &amp; II</td>
</tr>
<tr>
<td></td>
<td>Michael Kaplan, MRA President and CEO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Louise Perkins, MRA Chief Science Officer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction by Ross King &amp; President Carter welcome video</td>
<td></td>
</tr>
<tr>
<td>8:45-9:15 am</td>
<td>Lecture: Jedd Wolchok, Memorial Sloan Kettering Cancer Center: Immunotherapy for melanoma – where do we go from here?</td>
<td></td>
</tr>
<tr>
<td>9:15-11:25 am</td>
<td>Session 1: Biological Basis of Therapeutic Resistance</td>
<td></td>
</tr>
<tr>
<td>9:15-9:40</td>
<td>Neal Rosen, Memorial Sloan Kettering Cancer Center: Development of an equipotent inhibitor of mutant RAF monomers and dimers</td>
<td></td>
</tr>
<tr>
<td>9:40-10:00</td>
<td>Piyush Gupta, Whitehead Institute: Mechanisms of tolerance to Ras pathway inhibition in BRAF-mutant melanomas</td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Brent Hanks, Duke University: Inhibiting the TGF-β signaling axis in the melanoma microenvironment</td>
<td></td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
10:40-11:00  Bin Zhang, Northwestern University: Overcoming resistance to agonist immunotherapeutics
11:00-11:25  Roger Lo, UCLA: Resistance to MAPK and PD-1 targeted therapies

11:25-11:55 am  Lecture: Richard Scolyer, University of Sydney: Using whole genome sequencing to reveal differences between acral, mucosal and cutaneous melanomas: Data from the Australian melanoma genome project

12:00-1:15 pm  Lunch and Fireside Chat: Genes: A Conversation on Cancer Causation and Cures........Salon III
Moderator: Michael Milken, Chairman, Milken Institute and MRA Board Member
Siddhartha Mukherjee, Columbia University
Antoni Ribas, UCLA
Steven Rosenberg, U.S. National Cancer Institute

1:30-2:20 pm  Session 2: Germline Influences on Melanoma....................................................... Salon I & II
1:30-1:55  Hensin Tsao, Massachusetts General Hospital: Mutational landscape of hereditary melanoma
1:55-2:20  Alan Spatz, Lady Davis Institute: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene

2:20-4:45 pm  Session 3: Models, Markers and New Targets....................................................... Salon I & II
Chair: Meenhard Herlyn
2:20-2:40  Scott Woodman, MD Anderson Cancer Center: Unraveling the functional effects of hallmark genetic aberrations in uveal melanoma
2:40-3:00  Yuhang Zhang, University of Cincinnati: A tale of two stories: Targeting cancer-associated fibroblasts in the melanoma microenvironment
3:00-3:20  Break
3:20-3:40  Alexander Boiko, University of California, Irvine: Activation of innate immunity and targeting of tumor infiltrating cells effectively suppresses melanoma metastasis
3:40-4:00  Christin Burd, Ohio State University: Ultraviolet radiation accelerates NRAS mutant melanoma genesis: A cooperative effect blocked by sunscreen
4:00-4:20  Tal Burstyn-Cohen, Hebrew University of Jerusalem: TAM receptors in melanoma: Mechanisms and therapeutic efficacy of novel inhibitors
4:20-4:45  Meenhard Herlyn, Wistar Institute: Targeting developmental pathways in melanoma

4:45 pm  Closing Remarks Day 1: Louise Perkins, MRA Chief Science Officer

5:30-6:30 pm  MRA Board Meeting (invitation only)

6:30-9:00 pm  Reception and Dinner..............................................................Teddy & The Bully Bar*
Dress: Casual  1200 19th Street, NW, (202) 872-8700
Reception 6:30-7 pm; Dinner 7:15 pm
Wednesday, February 15th

6:30-10:00 am  Registration open............................................................................................................. Salon Ballroom Foyer

7:00-8:30 am  General Breakfast................................................................................................................Salon III

7:00-8:30 am  Industry Roundtable Breakfast (by invitation only)..........................................................Plaza Ballroom

8:40-8:45 am  Opening Remarks Day 2: Kristen Mueller, MRA Scientific Program Director...............Salon I & II

8:45-11:40 am  Session 4: Overcoming Difficult to Treat Disease
Chair: Sheri Holmen

8:45-9:10  Tanja de Gruijl, VUMC: Harnessing the sentinel lymph node to limit metastatic melanoma

9:10-9:30  James Moon, University of Michigan: Vaccine nanodiscs for personalized cancer immunotherapy

9:30-9:50  Xu Chen, UCSF: RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma

9:50-10:15  Andrew Aplin, Thomas Jefferson University: Targeted inhibitors in cutaneous and uveal melanoma: Combinations, reporters and schedules

10:15-10:35  Break

10:35-10:55  Jessie Villanueva, Wistar Institute: A promising BETi/MEKi combination strategy for NRAS mutant melanomas

10:55-11:15  Ana Anderson, Brigham and Women’s Hospital: Harnessing Tim-3 pathway blockade for melanoma immunotherapy

11:15-11:40  Sheri Holmen, University of Utah: Identification and characterization of drivers of melanoma brain metastasis

11:40-12:20 pm  Panel Discussion: News from the Field: What’s going well and what remains to be done?
Reinhard Dummer, University Hospital Zurich
Keith Flaherty, Massachusetts General Hospital
Howard Kaufman, Rutgers University
Grant McArthur, Peter MacCallum Cancer Centre
Susan Swetter, Stanford University
Jennifer Wargo, MD Anderson Cancer Center
Suzanne Topalian, Johns Hopkins University (Chair)

12:20-12:30 pm  Closing Remarks: Elliott Sigal, MRA Board Member

12:30-1:30 pm  Lunch available and departures..........................................................................................Salon III